Highlights from the 36th EORTC-NCI-AACR Symposium 2024

The 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held at the CCIB in Barcelona on October 23-25 2024.

ENA 2024 served as a premier event focused on drug development and translational research, with a particular emphasis on preclinical and phase I studies. The symposium facilitated comprehensive scientific discussions on the latest advancements in targets and therapeutics.

Drawing a global audience of academics, scientists, and leaders in the pharmaceutical industry, this event provided a platform for detailed discussions on innovative developments in drug discovery, target selection, and the impact of new discoveries in molecular biology.

Here are some highlights from the event:

AACR:

“ENASymp24 cochairs Elisabeth de Vries and Timothy A. Yap welcome attendees to the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics this morning in Barcelona.”

EORTC:

“ENASymp24 latest news: Scientists create cancer patients’ ‘digital twins’ to predict how well treatments may work. Read more.”

Paolo Tarantino:

“Wonderful ENASymp24 keynote lecture on immunotherapy and microbiome by Jennifer Wargo.

The 1st neoadjuvant immunotherapy topic in the next 5 years: more cures, less surgery!

And, hopefully, less toxicities too.”

Toni Choueiri:

“Chalabi Plots all on display in Niche trials during ENASymp24 session on neoadjuvant drugs and trials designs.

Myriam Chalabi is defining the neoadjuvant GI field in immunotherapy! A trailblazer!”

Jesús Fuentes Antrás:

“Exciting updates on biomarker discovery, targeting KRAS, FGFR3, MTAPloss, and novel ADCs at ENASymp24 towards more specific, less toxic therapies for more patients. Many thanks to EORTC, NCI, AACR for an insightful meet at the forefront of cancer drug development.”

Capu Baldini:

“Great talk by Stéphane Champiat on emerging opportunities for the prediction of irAEs ENASymp24:

• importance of networks
•  integrate PROs
• use innovative imaging
• wearable biosensors.”

Rick Buck:

“It was nice to catch up with CEO of EORTC, Dr. Denis Lacombe last night at the ENASymp24 speakers dinner in Barcelona. Congrats to all involved with this great meeting.”

Ute Jungwirth:

“Having a great time exploring lots of exciting research at this year’s ENAsymp24 in the beautiful city of Barcelona.”

Paolo Tarantino:

“ENASymp24 day 3: Heather Parsons from Dana-Farber’s Breast Oncology Center reviews the current evidence and anticipated evolutions in the assessment of minimal residual disease to guide cancer treatment. Critical to utilize highly sensitive, fit for purpose assays, and to prove their clinical utility.”

Raffaele Colombo:

“Such an honor and a pleasure to discuss ADCs this morning at the ENASymp24 and share the stage with Paolo Tarantino, Barbara Pistilli, Giuseppe Curigliano…a fantastic faculty!!

And a special thanks to Sandra Misale for taking photos during our talks!”

EORTC:

“ENASymp24 latest news: New ‘mini-protein’ carries radiation dose directly to tumours without harming healthy tissues
Read more.”

Carlota Pagès Geli:

“Had the great opportunity to attend the 36th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics. Really interesting talks and good networking!

Check out our work here.”

David Hong:

“Our new and great recruit Stéphane Champiat giving a great talk on immune biomarkers at ENASymp24!”

Sandra Misale:

“RAS revolution! response and tolerability and great enthusiasm! Awesome presentation by David Hong the excitement on clinical performance of KRAS inhibitors seems neverending!”

Kristina Jenei:

“Love a good timeline.

Was a great experience presenting the keynote lecture on our work about Project Orbis at ENASymp24 in Barcelona this past week.

Check out work here.”

EORTC:

“ENASymp24 latest news: Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors. Read more.”

Paolo Tarantino:

“Such an honor to co-chair the ENASymp24 New Drugs on the Horizon Session. Brings hope to see so much innovation in the oncology pipeline, with novel ADCs, IO and targeted drugs all promising to help us treat cancer better. Soon.”

Norbert Kraut:

“Exciting progress on targeting KRAS at ENASymp24. Outstanding presentations by Sandra Misale, Channing Der, David Hong and Jayesh Desai on drugging RAS. Many thanks to EORTC, NCI andAACR for organizing a wonderful meeting in Barcelona.”

Jia (Jenny) Liu:

“KRAS inhibitors are a game changer esp in pancreatic cancer. Exciting tolerability and efficacy of KRAS(on) inhibitor RMC-6236 presented by David Hong at ENAsymp24. Registrational PIII trial open.”

EORTC:

“A huge thank you to all our sponsors, exhibitors, and partners for their support at the 36th EORTC, AACR, NCI Symposium in Barcelona!”

More posts featuring the EORTC-NCI-AACR Symposium.